Tecartus (brexucabtagene autoleucel)

pCPA File Number: 21582

Negotiation Status:

Concluded with an LOI

Indication(s):

For the treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi)

Sponsor/Manufacturer:

Gilead Sciences Canada Inc.

CADTH Project Number:

PG0219

pCPA Engagement Letter Issued:

2021-11-22

Negotiation Process Concluded:

2022-11-10